Viking Therapeutics Inc VKTX.O:
VIKING THERAPEUTICS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2 VENTURE-ORAL DOSING TRIAL OF VK2735 TABLET FORMULATION IN PATIENTS WITH OBESITY
VIKING THERAPEUTICS INC - STUDY ACHIEVES ENDPOINTS WITH SIGNIFICANT WEIGHT REDUCTION USING VK2735
VIKING THERAPEUTICS INC - UP TO 12.2% MEAN WEIGHT LOSS WITH VK2735 AFTER 13 WEEKS
VIKING THERAPEUTICS INC - VK2735 SHOWN TO BE SAFE AND WELL-TOLERATED IN 13-WEEK STUDY